第一型糖尿病治療藥物:到2018年為止的開發平台評估與市場預測

第一型糖尿病治療藥物:到2018年為止的開發平台評估與市場預測 是由出版商GlobalData在2011年10月所出版的。 這份英文市場調查報告書包含Pages: 102 價格從美金3500起跳。

簡介

第一型糖尿病市場在2005年∼2010年以年複合成長率17.4%擴大，並達到23億3100萬美金。今後也將以年複合成長率8.7%繼續擴大，預計到2018年將達到45億5240萬美金。美國、歐洲主要五國，以及日本的糖尿病得病率上升和既存治療法的平均成本增加，對糖尿病意識的提高等因素，都推動著市場的成長。

本報告提供第一型糖尿病的概要與診斷，概論治療方法，治療藥物市場的規模與2018年為止的預測，彙整主要各市場趨勢，開發平台，參與企業簡介等資料，為您概述為以下內容。

第1章 目錄

第2章 第一型糖尿病治療藥物:簡介

• 疾病概要
• 免疫學
• 病因及病理學
• 症狀
• 一般所使用的診斷檢查
• 第一型糖尿病的治療與管理方法
• 報告指南

第3章 市場特徵

• 全球市場規模(2005∼2010年)
• 全球市場預測(2010∼2018年)
• 美國市場規模
• 美國市場預測
• 法國市場規模
• 法國市場預測
• 德國市場規模
• 德國市場預測
• 義大利市場規模
• 義大利市場預測
• 西班牙市場規模
• 西班牙市場預測
• 英國國市場規模
• 英國市場預測
• 日本市場規模
• 日本市場預測
• 推動市場的要素與阻礙要素
• 機會與未滿足需求分析
• 要點

第4章 競爭評估

• 概要
• 策略性競爭企業評估
• 已上市的主要產品簡介
  • Apidra
  • Humalog
  • Novolog
  • Lantus
  • Levemir
  • Symlin
• 要點

第5章 開發平台評估

• 概要
• 策略性開發平台評估
• 各開發階段開發平台
• 各作用機制開發平台
• 臨床開發中的潛力治療藥物
• 臨床開發中的潛力治療藥物分子簡介
• 要點

第6章 臨床實驗藍圖

• 各國
• 各階段
• 各治療狀況
• 整體臨床實驗委託者
• 主要臨床實驗委託者
• 參與計劃的主要企業

第7章 策略性評估

• 影響未來市場的主要活動
• 未來市場競爭的影響

第8章 未來的企業

• 簡介
• 企業簡介
  • BioDelivery sciences International, Inc
  • Diamyd Medical AB
  • Evotec Aktiengesellschaft
  • GlaxoSmithKline plc
  • Generex Biotechnology Corporation
  • Halozyme Therapeutics, Inc
  • MacroGenics, Inc
  • MannKind Corporation
  • Novo Nordisk A/S
  • 其他

第9章 專利與合作交易

第10章 附錄

圖表

目錄

Summary

GlobalData, the industry analysis specialist, has released its new report, "Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Type 1 Diabetes Therapeutics market. The report identifies the key trends shaping and driving the global Type 1 Diabetes Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Type 1 Diabetes Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Type 1 Diabetes Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Type 1 Diabetes Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Type 1 Diabetes Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Type 1 Diabetes Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Type 1 Diabetes Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Type 1 Diabetes Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Type 1 Diabetes Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global Type 1 Diabetes Therapeutics market landscape? - Identify, understand and capitalize.

1. Table of contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Type 1 Diabetes Therapeutics - Introduction

• 2.1 Disease Overview
• 2.2 Epidemiology
• 2.3 Etiology and Pathophysiology
• 2.4 Signs and Symptoms
• 2.5 Commonly Used Diagnostic Tests
• 2.6 Treatment and Management Options for Type 1 Diabetes
  • 2.6.1 Types of Insulin
• 2.7 GlobalData Pipeline Report Guidance

3. Type 1 Diabetes Therapeutics - Market Characterization

• 3.1 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Global
• 3.2 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Global
• 3.3 Type 1 Diabetes Therapeutics Market Size (2005-2010) - The US
• 3.4 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - The US
• 3.5 Type 1 Diabetes Therapeutics Market Size (2005-2010) - France
• 3.6 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - France
• 3.7 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Germany
• 3.8 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Germany
• 3.9 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Italy
• 3.10 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Italy
• 3.11 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Spain
• 3.12 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Spain
• 3.13 Type 1 Diabetes Therapeutics Market Size (2005-2010) - The UK
• 3.14 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - The UK
• 3.15 Type 1 Diabetes Therapeutics Market Size (2005-2010) - Japan
• 3.16 Type 1 Diabetes Therapeutics Market Forecast (2010-2018) - Japan
• 3.17 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market
  • 3.17.1 Drivers for the Type 1 Diabetes Therapeutics Market
  • 3.17.2 Barriers for the Type 1 Diabetes Therapeutics Market
• 3.18 Opportunity and Unmet Need Analysis
• 3.19 Key Takeaway

4. Type 1 Diabetes Therapeutics - Competitive Assessment

• 4.1 Overview
• 4.2 Strategic Competitor Assessment
• 4.3 Product Profiles for the Major Marketed Products in the Type 1 Diabetes Therapeutics Market
  • 4.3.1 Apidra (insulin glulisine)
  • 4.3.2 Humalog (insulin lispro)
  • 4.3.3 Novolog (insulin aspart)
  • 4.3.4 Lantus (insulin glargine)
  • 4.3.5 Levemir (insulin detemir)
  • 4.3.6 Symlin (pramlintide acetate)
• 4.4 Key Takeaway

5. Type 1 Diabetes Mellitus Therapeutics - Pipeline Assessment

• 5.1 Overview
• 5.2 Strategic Pipeline Assessment
• 5.3 Type 1 Diabetes Therapeutics Pipeline - Pipeline by Phases of Development
  • 5.3.1 Type 1 Diabetes Therapeutics - Phase III Pipeline
  • 5.3.2 Type 1 Diabetes Therapeutics - Phase II Pipeline
  • 5.3.3 Type 1 Diabetes Therapeutics - Phase I Pipeline
  • 5.3.4 Type 1 Diabetes Therapeutics - Pre-Clinical Pipeline
  • 5.3.5 Type 1 Diabetes Therapeutics - Discovery
  • 5.3.6 Technology Trends Analytic Framework
• 5.4 Type 1 Diabetes Therapeutics Market - Pipeline by Mechanism of Action
• 5.5 Type 1 Diabetes Therapeutics - Promising Drugs in Clinical Development
• 5.6 Molecule Profile for Promising Drugs in Clinical Development
  • 5.6.1 Degludec (NN1250)
  • 5.6.2 DiaPep277
  • 5.6.3 Generex Oral-lyn
• 5.7 Others Drugs Profile in Clinical Development
  • 5.7.1 Afrezza (insulin human [rDNA origin])
  • 5.7.2 Diamyd
  • 5.7.3 Linjeta (formerly known as VIAject)
  • 5.7.4 Otelixizumab
  • 5.7.5 Teplizumab
• 5.8 Key Takeaway

6. Type 1 Diabetes Therapeutics - Clinical Trial Mapping

• 6.1 Clinical Trials by Region and Country
• 6.2 Clinical Trials by Phase
• 6.3 Clinical Trials by Trial Status
• 6.4 Clinical Trial Mapping by Sponsors
• 6.5 Prominent Sponsors
• 6.6 Top Companies Participating in Type 1 Diabetes Therapeutics Clinical Trials

7. Type 1 Diabetes Therapeutics - Strategic Assessment

• 7.1 Key Events Impacting the Future Market
• 7.2 Type 1 Diabetes Therapeutics: Implications for Future Market Competition

8. Type 1 Diabetes Therapeutics - Future Players

• 8.1 Introduction
• 8.2 Company Profiles
  • 8.2.1 BioDelivery Sciences International, Inc
  • 8.2.2 Diamyd Medical AB
  • 8.2.3 Evotec Aktiengesellschaft
  • 8.2.4 GlaxoSmithKline plc
  • 8.2.5 Generex Biotechnology Corporation
  • 8.2.6 Halozyme Therapeutics, Inc.
  • 8.2.7 MacroGenics, Inc.
  • 8.2.8 MannKind Corporation
  • 8.2.9 Novo Nordisk A/S
  • 8.2.10 Other Companies in the Type 1 Diabetes Therapeutics Market

9. Type 1 Diabetes Therapeutics - Licensing and Partnership Deals

10. Type 1 Diabetes Therapeutics - Appendix

• 10.1 Market Definitions
• 10.2 Abbreviations
• 10.3 Methodology
  • 10.3.1 Coverage
  • 10.3.2 Secondary Research
  • 10.3.3 Forecasting
  • 10.3.4 Primary Research
  • 10.3.5 Expert Panel Validation
• 10.4 Contact Us
• 10.5 Disclaimer
• 10.6 Bibliography

• Table 1: Recommended Diagnostic Test for Diabetes Mellitus
• Table 2: Plasma Blood Glucose and A1C Goals for Type 1 Diabetes By Age Group
• Table 3: Types of Insulin Preparations
• Table 4: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2005-2010
• Table 5: Type 1 Diabetes Therapeutics Market, Global, Forecast ($m), 2010-2018
• Table 6: Type 1 Diabetes Therapeutics Market, The US, Revenue ($m), 2005-2010
• Table 7: Type 1 Diabetes Therapeutics Market, The US, Forecasts ($m), 2010-2018
• Table 8: Type 1 Diabetes Therapeutics Market, France, Revenue ($m), 2005-2010
• Table 9: Type 1 Diabetes Therapeutics Market, France, Forecasts ($m), 2010-2018
• Table 10: Type 1 Diabetes Therapeutics Market, Germany, Revenue ($m), 2005-2010
• Table 11: Type 1 Diabetes Therapeutics Market, Germany, Forecasts ($m), 2010-2018
• Table 12: Type 1 Diabetes Therapeutics Market, Italy, Revenue ($m), 2005-2010
• Table 13: Type 1 Diabetes Therapeutics Market, Italy, Forecasts ($m), 2010-2018
• Table 14: Type 1 Diabetes Therapeutics Market, Spain, Revenue ($m), 2005-2010
• Table 15: Type 1 Diabetes Therapeutics Market, Spain, Forecasts ($m), 2010-2018
• Table 16: Type 1 Diabetes Therapeutics Market, The UK, Revenue ($m), 2005-2010
• Table 17: Type 1 Diabetes Therapeutics Market, The UK, Forecasts ($m), 2010-2018
• Table 18: Type 1 Diabetes Therapeutics Market, Japan, Revenue ($m), 2005-2010
• Table 19: Type 1 Diabetes Therapeutics Market, Japan, Forecasts ($m), 2010-2018
• Table 20: Apidra - Efficacy Result of 26 Week Study Comparing Apidra with Insulin Lispro, 2011
• Table 21: Apidra - Efficacy Result of 26 Week Study Comparing Apidra with Regular Insulin, 2011
• Table 22: Apidra - Adverse Reactions Observed in Pooled Studies in Type 1 Diabetic Adults, 2011
• Table 23: Type 1 Diabetes Therapeutics Market, Humalog, Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Month Cross Over Studies, 2011
• Table 24: Humalog - Results of a Two Month Study Comparing the Use of Humalog and Humulin With Sulfonyluria (SU) Therapy, 2011
• Table 25: Type 1 Diabetes Therapeutics Market, Novolog, Glycemic Parameters at the End of 24 Week Study, 2011
• Table 26: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Efficacy, 2011
• Table 27: Type 1 Diabetes Therapeutics Market, Lantus, Adverse Events in 28 Week Clinical Trials of Adults and Children With Type 1 Diabetes, 2011
• Table 28: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Safety, 2011
• Table 29: Levemir - Efficacy Result in 16 Week Non Blinded Study, 2011
• Table 30: Type 1 Diabetes Therapeutics - Phase III Pipeline, 2011
• Table 31: Type 1 Diabetes Therapeutics - Phase II Pipeline, 2011
• Table 32: Type 1 Diabetes Therapeutics - Phase I Pipeline, 2011
• Table 33: Type 1 Diabetes Therapeutics - Pre-Clinical Pipeline, 2011
• Table 34: Type 1 Diabetes Therapeutics - Discovery, 2011
• Table 35: Type 1 Diabetes Therapeutics - Most Promising Drugs in Clinical Development, 2011
• Table 36: Type 1 Diabetes Therapeutics - Clinical Trials by Country, 2011
• Table 37: Type 1 Diabetes Therapeutics - Clinical Trials by Phase, 2011
• Table 38: Type 1 Diabetes Therapeutics - Clinical Trials by Status, 2011
• Table 39: Type 1 Diabetes Therapeutics - Overall Sponsors, 2011
• Table 40: Type 1 Diabetes Therapeutics - Prominent Sponsors, 2011
• Table 41: Type 1 Diabetes Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
• Table 42: BioDelivery Sciences International, Inc.- Type 1 Diabetes, Pipeline, 2011
• Table 43: Diamyd Medical AB - Type 1 Diabetes, Pipeline, 2011
• Table 44: Evotec - Metabolic Disorder, Pipeline, 2011
• Table 45: GlaxoSmithKline plc - Metabolic Disorder, Pipeline, 2011
• Table 46: Generex Biotechnology Corporation-Metabolic Disorder, Pipeline, 2011
• Table 47: Halozyme Therapeutics-Metabolic Disorder, Pipeline, 2011
• Table 48: Halozyme Therapeutics-Metabolic Disorder, Pipeline, 2011
• Table 49: MannKind Corporation -Metabolic Disorder, Pipeline, 2011
• Table 50: Novo Nordisk A/S - Type 1 Diabetes, Pipeline, 2011
• Table 51: Type 1 Diabetes Therapeutics Market - Future Players
• Table 52: Type 1 Diabetes-Global, Deals, 2011

• Figure 1: Pathogenesis of Type 1 Diabetes
• Figure 2: Type 1 Diabetes Therapeutics Market, Global, Revenue ($m), 2005-2010
• Figure 3: Type 1 Diabetes Therapeutics Market, Global, Forecast ($m), 2010-2018
• Figure 4: Type 1 Diabetes Therapeutics Market, The US, Forecast ($m), 2005-2010
• Figure 5: Type 1 Diabetes Therapeutics Market, The US, Forecasts ($m), 2010-2018
• Figure 6: Type 1 Diabetes Therapeutics Market, France, Revenue ($m), 2005-2010
• Figure 7: Type 1 Diabetes Therapeutics Market, France, Forecast ($m), 2010-2018
• Figure 8: Type 1 Diabetes Therapeutics Market, Germany, Revenue ($m), 2005-2010
• Figure 9: Type 1 Diabetes Therapeutics Market, Germany, Forecast ($m), 2010-2018
• Figure 10: Type 1 Diabetes Therapeutics Market, Italy, Revenue ($m), 2005-2010
• Figure 11: Type 1 Diabetes Therapeutics Market, Italy, Forecast ($m), 2010-2018
• Figure 12: Type 1 Diabetes Therapeutics Market, Spain, Revenue ($m), 2005-2010
• Figure 13: Type 1 Diabetes Therapeutics Market, Spain, Forecast ($m), 2010-2018
• Figure 14: Type 1 Diabetes Therapeutics Market, The UK, Revenue ($m), 2005-2010
• Figure 15: Type 1 Diabetes Therapeutics Market, The UK, Forecast ($m), 2010-2018
• Figure 16: Type 1 Diabetes Therapeutics Market, Japan, Revenue ($m), 2005-2010
• Figure 17: Type 1 Diabetes Therapeutics Market, Japan, Forecasts ($m), 2010-2018
• Figure 18: Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics Market
• Figure 19: Type 1 Diabetes Therapeutics - Strategic Competitor Assessment, 2011
• Figure 20: Type 1 Diabetes Therapeutics - Pipeline by Phase of Development, 2011
• Figure 21: Type 1 Diabetes Therapeutics - Technology Trends Analytics Framework, 2011
• Figure 22: Type 1 Diabetes Therapeutics - Pipeline by Mechanism of Action, 2011
• Figure 23: Type 1 Diabetes Therapeutics - Clinical Trials by Country, 2011
• Figure 24: Type 1 Diabetes Therapeutics - Clinical Trials by Phase, 2011
• Figure 25: Type 1 Diabetes Therapeutics - Clinical Trials by Status, 2011
• Figure 26: Type 1 Diabetes Therapeutics - Overall Sponsors, 2011
• Figure 27: Type 1 Diabetes Therapeutics - Prominent Sponsors, 2011
• Figure 28: Type 1 Diabetes Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
• Figure 29: Type 1 Diabetes Therapeutics Market, Drivers and Barriers, 2011
• Figure 30: Implications for Future Market Competition in the Type 1 Diabetes Market, 2011
• Figure 31: Type 1 Diabetes Therapeutics Market - Pipeline by Company, 2011
• Figure 32: GlobalData Market Forecasting Model

相關商品

糖尿病相關市場調查報告書

Glucagon-Like Peptide-1(GLP-1)受體激動劑:目標開發平台及相關利益者分析(2012年)
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
價格 : US $ 2600
出版日期 : 2012年03月

全球糖尿病治療藥物市場(到2017年為止):更好的血糖管理和潛在的低血糖風險的減輕與DPP-IV抑制劑和GLP-1作用藥的市場佔有率擴大相關
Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
價格 : US $ 3500
出版日期 : 2012年02月

第二型糖尿病:全球藥物預測和治療分析
Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020
價格 : US $ 6995
出版日期 : 2012年02月

GlobalData發行的製藥相關市場調查報告書

肺支氣管發育不良:全球臨床實驗檢討

Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

病毒性呼吸道感染疾病:全球臨床實驗檢討

Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

心搏過速 (快速心律不整):全球臨床實驗檢討

Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012

價格 : US $ 1000

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!